IMR Press / FBL / Volume 19 / Issue 7 / DOI: 10.2741/4275

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Novel biomarker for prostate cancer diagnosis by MRS
Show Less
1 Department of Physics, School of Basic and Applied Sciences, Galgotias University, Greater Noida, India
2 Department of Bioinformatics, School of Computer Sciences, Galgotias University, Greater Noida, India
3 Medical Biotechnology Division, School of Biosciences and Technology, VIT University, Vellore 632014, Tamil Nadu, India
4 Department of Radiation Oncology, Apollo Specialty Hospital, Chennai- 600035, India
5 Department of Chemistry, National Sun Yat-sen University, Kaohsiung, Taiwan, ROC
6 Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon, 200704, Korea
Academic Editors:Chiranjib Chakraborty, George Priya Doss C
Front. Biosci. (Landmark Ed) 2014, 19(7), 1186–1201;
Published: 1 June 2014
(This article belongs to the Special Issue Novel biomarker for prostate cancer diagnosis by MRS)

Magnetic resonance spectroscopy (MRS) is a prospective tool for characterization of the chemical composition of tissues. In vivo MRS can be used for metabolite profiling in the prostate tissue to discriminate non-invasively carcinomas and healthy prostate. In this article different prostate metabolites have been discussed and how to exploit the MRS technique for the estimation of metabolites in prostate tissue quantitatively is elucidated. Choline, citrate, creatine, myo-inositol metabolites can be considered as biomarker for localization of malignancy in the prostate and their ratio can be used for the determination of cancer tissue in the prostate gland.

Magnetic Resonance Spectroscopy
Prostate Cancer
Back to top